Lilly's Foundayo (Oral GLP-1) Earns FDA Approval April 1

Foundayo, an oral GLP-1, received FDA approval on April 1 based on ATTAIN-1 (non-diabetic obesity/overweight) and ATTAIN-2 (diabetes plus obesity) data. Maximum-dose mean weight loss was 27.3 lbs (12.4%).